Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: A randomized, placebo-controlled trial

Endocrine

Volumn 45, Issue 2, 2014, Pages 293-301

  Tang, Wen Hao ^a   Lin, Fu Huang ^b   Lee, Chien Hsing ^a,b   Kuo, Feng Chih ^a   Hsieh, Chang Hsun ^a   Hsiao, Fone Ching ^a   Hung, Yi Jen ^a,b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Adhesion molecules and diabetic nephropathy; Cilostazol; Microalbuminuria

Indexed keywords

CILOSTAZOL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; ORAL ANTIDIABETIC AGENT; PLACEBO; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; UNSPECIFIED SIDE EFFECT; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ALBUMINURIA; ANTI-INFLAMMATORY AGENTS; CHEMOKINE CCL2; CREATININE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; E-SELECTIN; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; TETRAZOLES; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84896736849     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-0002-3     Document Type: Article

References (44)

1. C.E. Lok, M.J. Oliver, D.M. Rothwell, J.E. Hux, The growing volume of diabetes-related dialysis: a population based study. Nephrol. Dial. Transplant. 19, 3098-3103 (2004)
2. G. Jerums, S. Panagiotopoulos, E. Premaratne, R.J. MacIsaac, Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat. Rev. Nephrol. 5, 397-406 (2009)
3. G. Remuzzi, A. Schieppati, P. Ruggenenti, Clinical practice. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 346, 1145-1151 (2002)
4. A.I. Adler, R.J. Stevens, S.E. Manley, R.W. Bilous, C.A. Cull, R.R. Holman, UKPDS Group, Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 63, 225-232 (2003)
5. M.A. Gall, Albuminuria in non-insulin-dependent diabetes mellitus. Prevalence, causes, and consequences. Dan. Med. Bull. 44, 465-485 (1997)
6. R. Retnakaran, C.A. Cull, K.I. Thorne, A.I. Adler, R.R. Holman, UKPDS Study Group, Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 55, 1832-1839 (2006)
7. C. Forsblom, V. Harjutsalo, L.M. Thorn et al., Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J. Am. Soc. Nephrol. 22, 537-544 (2001)
8. A. Patel, S. MacMahon, J. Chalmers et al., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560-2572 (2008)
9. K. Phisitkul, K. Hegazy, T. Chuahirun et al., Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Am. J. Med. Sci. 335, 284-291 (2008)
10. G. Deferrari, M. Ravera, V. Berruti, G. Leoncini, L. Deferrari, Optimizing therapy in the diabetic patient with renal disease: antihypertensive treatment. J. Am. Soc. Nephrol. 15(Suppl 1), S6-S11 (2004)
11. G.F. Strippoli, C. Bonifati, M. Craig, S.D. Navaneethan, J.C. Craig, Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst. Rev. CD006257 (2006)
12. B.B. McCormick, A. Sydor, A. Akbari, D. Fergusson, S. Doucette, G. Knoll, The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am. J. Kidney Dis. 52, 454-463 (2008)
13. J.F. Navarro, C. Mora, M. Muros et al., Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J. Am. Soc. Nephrol. 16, 2119-2126 (2005)
14. J.F. Navarro, C. Mora, M. Muros, J. García, Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am. J. Kidney Dis. 33, 458-463 (1999)
15. Y.M. Chen, S.L. Lin, W.C. Chiang, K.D. Wu, T.J. Tsai, Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int. 69, 1410-1415 (2006)
16. A. Giustina, S. Bossoni, A. Cimino et al., Picotamide, a dual TXB synthase inhibitor and TXB receptor antagonist reduces exercise-induced albuminuria in microalbuminuric patients with NIDDM. Diabetes 42, 178-182 (1993)
17. A. Giustina, P. Perini, P. Desenzani et al., Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes 47, 423-430 (1998)
18. T. Shinoda-Tagawa, Y. Yamasaki, S. Yoshida et al., A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia 45, 188-194 (2002)
19. P.D. Thompson, R. Zimet, W.P. Forbes, P. Zhang, Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am. J. Cardiol. 90, 1314-1319 (2002)
20. N.K. Agrawal, R. Maiti, D. Dash, B.L. Pandey, Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacol. Res. 56, 118-123 (2007)
21. M.J. Kim, K.G. Park, K.M. Lee et al., Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension 45, 552-556 (2005)
22. S.M. Grenon, J. Gagnon, Y. Hsiang et al., Video in clinical medicine. Ankle-brachial index for assessment of peripheral arterial disease. N. Engl. J. Med. 361(19), e40 (2009)
23. L. Gao, F. Wang, B. Wang et al., Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-kappa B-dependent down-regulation of vascular cell adhesion molecule-1 expression. J. Pharmacol. Exp. Ther. 318, 53-58 (2006)
24. Y. Hattori, K. Suzuki, A. Tomizawa et al., Cilostazol inhibits cytokine-induced nuclear factor-kappa B activation via AMP-activated protein kinase activation in vascular endothelial cells. Cardiovasc. Res. 81, 133-139 (2009)
25. F. Wang, M. Li, L. Cheng et al., Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats. Life Sci. 83, 828-835 (2008)
26. X. Wang, L. Yan, W. Chen, L. Xu, X. Zhang, The renal protective effects of cilostazol on suppressing pathogenic thrombospondin-1 and transforming growth factor-beta expression in streptozotocin-induced diabetic rats. J. Int. Med. Res. 37, 145-153 (2009)
27. J. Watanabe, Y. Sako, F. Umeda, H. Nawata, Effects of cilostazol, a phosphodiesterase inhibitor, on urinary excretion of albumin and prostaglandins in non-insulin-dependent diabetic patients. Diabetes Res. Clin. Pract. 22, 53-59 (1993)
28. S.L. Lin, Y.M. Chen, C.T. Chien, W.C. Chiang, C.C. Tsai, T.J. Tsai, Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J. Am. Soc. Nephrol. 13, 2916-2929 (2002)
29. A. Yagmurlu, M.E. Boleken, D. Ertoy, M. Ozsan, I.H. Gokcora, H. Dindar, Preventive effect of pentoxifylline on renal scarring in rat model of pyelonephritis. Urology 61, 1037-1041 (2003)
30. N. Katakami, Y.S. Kim, R. Kawamori, Y. Yamasaki, The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation 121, 2584-2591 (2010)
31. R.B. Goldberg, Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J. Clin. Endocrinol. Metab. 94, 3171-3182 (2009)
32. P. Clausen, P. Jacobsen, K. Rossing, J.S. Jensen, H.H. Parving, B. Feldt-Rasmussen, Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabet. Med. 17, 644-649 (2000)
33. J. Lin, F.B. Hu, E.B. Rimm, N. Rifai, G.C. Curhan, The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. Kidney Int. 69, 336-342 (2006)
34. E. Galkina, K. Ley, Vascular adhesion molecules in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27, 2292-2301 (2007)
35. F. Chiarelli, F. Cipollone, A. Mohn et al., Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care 25, 1829-1834 (2002)
36. K. Tashiro, I. Koyanagi, A. Saitoh et al., Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J. Clin. Lab. Anal. 16(1), 1-4 (2002)
37. T. Morii, H. Fujita, T. Narita et al., Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J. Diabetes Complications 17, 11-15 (2003)
38. F.Y. Chow, D.J. Nikolic-Paterson, E. Ozols, R.C. Atkins, B.J. Rollin, G.H. Tesch, Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 69, 73-80 (2006)
39. K. Ina, H. Kitamura, T. Okeda et al., Vascular cell adhesion molecule-1 expression in the renal interstitium of diabetic KKAy mice. Diabetes Res. Clin. Pract. 44, 1-8 (1999)
40. S.C. Lim, A.E. Caballero, P. Smakowski, F.W. LoGerfo, E.S. Horton, A. Veves, Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care 22, 1865-1870 (1999)
41. C.D. Stehouwer, M.A. Gall, J.W. Twisk, E. Knudsen, J.J. Emeis, H.H. Parving, Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51, 1157-1165 (2002)
42. C. Gazzaruso, A. Coppola, C. Falcone, C. Luppi, T. Montalcini, E. Baffero, Transcutaneous oxygen tension as a potential predictor of cardiovascular events in type 2 diabetes. Diabetes Care 36, 1720-1725 (2013)
43. J. Apelqvist, Diagnostics and treatment of diabetic foot. Endocrine 41, 384-397 (2012)
44. C. Meisinger, M. Heier, R. Landgraf, M. Happich, H.E. Wichmann, W. Piehlmeier, Albuminuria, cardiovascular risk factors and disease management in subjects with type 2 diabetes: a cross-sectional study. BMC Health Serv. Res. 8, 226 (2008)